Retatrutide for Weight Loss: What to Know About the Triple-Agonist Drug
- Retatrutide is an investigational triple receptor agonist developed by Eli Lilly and Company that targets GIP, GLP-1, and glucagon receptors for weight management, yielding average weight loss results...
- While older medications like semaglutide target only the GLP-1 receptor and tirzepatide targets both GIP and GLP-1 receptors, retatrutide introduces a third receptor agonist targeting glucagon, earning it...
- Results from three 80-week Phase 3 trials evaluated the highest 12 mg dose of retatrutide across distinct adult patient populations, drugs.com reported.
Retatrutide is an investigational triple receptor agonist developed by Eli Lilly and Company that targets GIP, GLP-1, and glucagon receptors for weight management, yielding average weight loss results in clinical trials that approach the scale of bariatric surgery, according to womenshealthmag.com, drugs.com, and health.usnews.com.
How Does Retatrutide Work Compared to Semaglutide and Tirzepatide?
While older medications like semaglutide target only the GLP-1 receptor and tirzepatide targets both GIP and GLP-1 receptors, retatrutide introduces a third receptor agonist targeting glucagon, earning it the label of a triple-G agonist or triple agonist, drugs.com reported. Activating the glucagon receptor alongside GIP and GLP-1 increases energy expenditure, delays gastric emptying, improves fat-cell metabolism, and reduces stored fat, according to drugs.com and womenshealthmag.com.
What Were the Weight Loss Results in Phase 3 Trials?
Results from three 80-week Phase 3 trials evaluated the highest 12 mg dose of retatrutide across distinct adult patient populations, drugs.com reported. Non-diabetic adults with obesity or overweight enrolled in the TRIUMPH-1 trial lost an average of 70.3 pounds, or 28.3 percent of their body weight, according to drugs.com. Participants with type 2 diabetes and obesity or overweight in the TRIUMPH-2 trial lost an average of 49.6 pounds, or 20.8 percent of their body weight, per drugs.com. Adults with severe obesity and heart disease in the TRIUMPH-3 trial lost an average of 55.8 pounds, or 22.6 percent of their body weight, drugs.com reported.
What Are the Clinical Safety Risks and Side Effects?
Gastrointestinal symptoms remain the most common adverse events reported in clinical trials, mirroring other incretin therapies, according to womenshealthmag.com. Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, noted in reporting by womenshealthmag.com that Phase 2 studies showed minor increases in heart rate that peaked around 24 weeks before subsiding independently. Early trials also identified mild to moderate dysesthesia, or altered skin sensation, as a novel side effect, womenshealthmag.com stated.
Why Are Doctors Warning Against Gray Market Versions?
Because retatrutide is an investigational drug that has not yet received approval from the U.S. Food and Drug Administration, it is available exclusively to participants in clinical trials, drugs.com reported. Unregulated versions sold through online gray markets lack quality control, consistent recipes, and safety assurances, womenshealthmag.com reported. The FDA received adverse event reports linked to gray market versions, including a July report of a woman who experienced cardiac arrest and a September report of a 49-year-old who suffered severe dehydration, malnutrition, fainting, and cardiac arrest, according to womenshealthmag.com.